Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

869407

registered interest
date	22/03/2018
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	Military Bases: York
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Defence, what plans his Department has to retain civilian support jobs in York following the planned closure of Queen Elizabeth Barracks and Imphal Barracks.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133921
answer	answer is ministerial correction date of answer 28/03/2018 answer text <p>Future planning for the civilian support jobs based in York are still in progress and the Department will work with the local Authority and the Government Property Agency to explore potential opportunities to keep civilian posts within the local area.</p><p>Civilian personnel will be managed in accordance with normal Departmental Policy and processes and formal Trades Union consultation will occur in advance of any site closure.</p> answering member constituency Aberconwy answering member printed Guto Bebb question first answered 28/03/2018 16:30:01 answering member 3910 label Biography information for Guto Bebb
tabling member	4079 label Biography information for Julian Sturdy

867387

registered interest
date	20/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential reduction in hospital admissions for people with cystic fibrosis were Orkambi to be made available on the NHS.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133362
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The Department has made no assessment itself. However, in developing its technology appraisal guidance, the National Institute for Health and Care Excellence, takes into account all the costs and savings associated with the treatment compared with existing clinical practice.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 27/03/2018 14:32:34 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

867419

registered interest
date	20/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Electronic Cigarettes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the potential savings to the public purse from the health service encouraging the uptake of e-cigarettes among smokers.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133394
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The potential financial impacts of e-cigarettes on the public purse are not yet fully understood. The evidence base is still evolving on these products, largely because vaping is still relatively new and the health effects may be very long term. Significant savings to the public purse are likely to arise only if smokers switch completely from smoked tobacco. The Government’s Tobacco Control Plan, published in July 2017, estimates that the National Health Service currently spends £2.5 billion on treating smoking-related diseases and Public Health England assess e-cigarettes to be at least 95% less harmful than smoked tobacco. Reduced harm may not translate exactly into proportional costs savings, but superficially this implies that vaping, as an alternative to smoking, may contribute to significant savings.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 27/03/2018 14:37:44 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

867420

registered interest
date	20/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Electronic Cigarettes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage smokers to give up by promoting the use of e-cigarettes.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133395
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The Department has been clear that for smokers, quitting smoking completely is the best way to improve health. E-cigarettes are not risk free. However, the evidence is increasingly clear that e-cigarettes are significantly less harmful to health than cigarettes and can help smokers to quit, particularly when combined with support from stop smoking services.</p><p> </p><p>The Government committed Public Health England (PHE), through the Tobacco Control Plan, published in 2017, to include messages about the relative safety of e-cigarettes in their quit smoking campaigns. PHE’s 2017 Stoptober campaign included e-cigarettes among the array of tools that smokers can use to help them quit and, in their New Year smoking health harms campaign, PHE reprised these messages. It is through this consistent messaging that the Government hopes to reverse the harmful, mistaken – and increasingly widespread – belief that vaping is no safer than smoking.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 27/03/2018 14:42:47 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

867178

registered interest
date	19/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will bring forward the scheduled review of the Cystic Fibrosis drug Orkambi.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133296
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The Government has made no such assessment itself. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources. NICE published guidance on the use of Orkambi for the treatment of cystic fibrosis in July 2016 and was not able to recommend it for routine use on the NHS.</p><p> </p><p>NICE has advised that it has not been notified of any new data published in February 2018 related to the use of Orkambi. NICE periodically reviews its technology appraisal guidance to determine whether any new evidence, including new trial data, has emerged that may affect its original recommendations. NICE is next scheduled to review its guidance on the use of Orkambi in July 2019, at which point it will conduct a search for new evidence. NICE’s guidance may be reviewed before the expected review date if significant new evidence emerges that is likely to change the recommendations. The company or any other stakeholder can alert NICE to new evidence in line with its established processes to request an early review.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 133299 question first answered 27/03/2018 11:54:59 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

867181

registered interest
date	19/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made for the implications for its policy of new data published by Vertex Pharmaceuticals in February 2018 on the Cystic Fibrosis drug Orkambi.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133299
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The Government has made no such assessment itself. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources. NICE published guidance on the use of Orkambi for the treatment of cystic fibrosis in July 2016 and was not able to recommend it for routine use on the NHS.</p><p> </p><p>NICE has advised that it has not been notified of any new data published in February 2018 related to the use of Orkambi. NICE periodically reviews its technology appraisal guidance to determine whether any new evidence, including new trial data, has emerged that may affect its original recommendations. NICE is next scheduled to review its guidance on the use of Orkambi in July 2019, at which point it will conduct a search for new evidence. NICE’s guidance may be reviewed before the expected review date if significant new evidence emerges that is likely to change the recommendations. The company or any other stakeholder can alert NICE to new evidence in line with its established processes to request an early review.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 133296 question first answered 27/03/2018 11:54:59 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

867182

registered interest
date	19/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions has his Department had with Cystic Fibrosis sufferers on the provision of the drug Orkambi by the NHS.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133300
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The Government met with the Cystic Fibrosis Trust, which represents patients with cystic fibrosis, in March 2017 to discuss access to the drug Orkambi. The Government has also had regular correspondence with patients with cystic fibrosis concerning the availability of Orkambi. We are also aware that NHS England has been in regular contact with the Cystic Fibrosis Trust about this matter.</p><p> </p><p>The Government welcomes the ongoing discussions between NHS England and the manufacturer of Orkambi, Vertex, to seek to agree a deal that would make Orkambi available to National Health Service patients in a way that represents value to the taxpayer.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 27/03/2018 11:56:18 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

856915

registered interest
date	07/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Eating Disorders: Children and Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support Clinical Commissioning Groups to meet national standards on the treatment of children and young people with eating disorders.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	131427
answer	answer is ministerial correction date of answer 14/03/2018 answer text <p>The access and waiting time standard for children and young people with eating disorders states that by 2020/21, evidence-based community eating disorder services for children and young people will be in place in all areas, ensuring that 95% of children in need receive treatment within one week for urgent cases, and four weeks for routine cases.</p><p> </p><p>For children and young people, the latest figures show that the waiting time standard for access to treatment for eating disorders is on track to be met as planned:</p><p>- 76.9% of patients started urgent treatment within one week in Q3 (October - December 2017); and</p><p>- 83.1% of patients started routine treatment within four weeks in Q3 (October – December 2017).</p><p> </p><p>The Department is investing £30 million a year to 2020 to support clinical commissioning groups in developing and enhancing eating disorder services for children and young people. There are now 70 new or expanded community eating disorders services in place.</p><p> </p><p>This funding is to support the commissioning of services to the standards set out in the NHS England and National Collaborating Centre for Mental Health Commissioning Guide, ‘Access and Waiting Time Standard for Children and Young People with an Eating Disorder’, which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2015/07/cyp-eating-disorders-access-waiting-time-standard-comm-guid.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2015/07/cyp-eating-disorders-access-waiting-time-standard-comm-guid.pdf</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 14/03/2018 15:37:54 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4079 label Biography information for Julian Sturdy

856916

registered interest
date	07/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Eating Disorders
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to introduce (a) access and (b) waiting times standards for adults with eating disorders on an equivalent basis to standards for people up to the age of 19.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	131428
answer	answer is ministerial correction date of answer 14/03/2018 answer text <p>A pathway for adults with eating disorders, together with detailed implementation guidance for providers, is being developed by the National Collaborating Centre for Mental Health in partnership with the National Institute for Health and Care Excellence. This work will be fully informed by the available evidence and the views of experts by experience.</p><p> </p><p>In parallel to this, a baseline data collection will be undertaken to measure existing levels of investment, capacity and activity across inpatient and community services for adults with eating disorders to assess the feasibility of introducing a mandatory waiting time standard.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 14/03/2018 15:35:26 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4079 label Biography information for Julian Sturdy

850730

registered interest
date	27/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to NHS dental care in (a) York, (b) North Yorkshire and (c) England.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	129970
answer	answer is ministerial correction date of answer 07/03/2018 answer text <p>NHS England has a legal duty to commission National Health Service dental services to meet the needs of the local population. NHS England also has arrangements in place to help patients who cannot find a local dentist that is accepting new patients.</p><p> </p><p>Access nationally remains high with 22.1 million adults having seen an NHS dentist in the last 24 months ending in 31 December 2017 and 6.9 million children having seen an NHS dentist in the last 12 months. However, there are areas where there is further to go to ensure that all those who want to access NHS dental care can do so.</p><p> </p><p>NHS England (Yorkshire and the Humber) is currently reviewing how it can improve access to NHS dentists from April 2018, prioritising areas where access is particularly difficult.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/03/2018 16:53:33 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy